Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting HIV-1 integrase.

Khampoune Sayasith1, Gilles Sauvé, Jocelyn Yelle

  • 1CRRA, Faculty of Veterinary Medicine, University of Montreal, PO Box 5000, St-Hyacinthe, Quebec, Canada J2S 7C6. sayasik@yahoo.ca

Expert Opinion on Therapeutic Targets
|January 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of bovine tumor necrosis factor-alpha-induced protein 6 in ovarian follicles during the ovulatory process and promoter activation in granulosa cells.

Endocrinology·2008
Same author

Gonadotropin-dependent regulation of the prostaglandin E2 receptor in equine preovulatory follicles during the ovulatory process in mares.

Molecular reproduction and development·2008
Same author

In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.

Antimicrobial agents and chemotherapy·2007
Same author

Gonadotropin-dependent regulation of bovine pituitary adenylate cyclase-activating polypeptide in ovarian follicles prior to ovulation.

Reproduction (Cambridge, England)·2007
Same author

Cloning of equine prostaglandin dehydrogenase and its gonadotropin-dependent regulation in theca and mural granulosa cells of equine preovulatory follicles during the ovulatory process.

Reproduction (Cambridge, England)·2007
Same author

Structure of the bovine VASAP-60/PRKCSH gene, functional analysis of the promoter, and gene expression analysis.

Gene·2007
Same journal

The biological role of CCR4 and its ligands CCL17 and CCL22 in atopic dermatitis: therapeutic implications and future directions.

Expert opinion on therapeutic targets·2026
Same journal

Hepatocyte nuclear factor 4α - prospects for therapeutic targeting.

Expert opinion on therapeutic targets·2026
Same journal

The role of bile acid receptors in cholestatic liver disease: pathophysiological insights and therapeutic advances.

Expert opinion on therapeutic targets·2026
Same journal

Molecular insights for targeting the Nrf1 pathway in hepatocellular carcinoma.

Expert opinion on therapeutic targets·2026
Same journal

Transient receptor potential (TRP) channels: an emerging therapeutic target for the treatment of cardiac hypertrophy.

Expert opinion on therapeutic targets·2026
Same journal

The AT<sub>2</sub> receptor as a potential target for autosomal dominant polycystic kidney disease therapy?

Expert opinion on therapeutic targets·2026
See all related articles

Human immunodeficiency virus Type 1 (HIV-1) integrase is crucial for viral DNA integration. This review explores HIV-1 integrase inhibitors as potential non-toxic therapeutics for AIDS, addressing drug resistance.

Area of Science:

  • Biochemistry
  • Virology
  • Drug Discovery

Background:

  • Human immunodeficiency virus Type 1 (HIV-1) integrase is essential for viral DNA integration into host chromosomes.
  • No cellular homologue exists, making HIV-1 integrase a unique therapeutic target.
  • Current HIV/AIDS treatments (reverse transcriptase and protease inhibitors) face side effects and drug resistance issues.

Purpose of the Study:

  • To review the biological functions of HIV-1 integrase.
  • To report on identified classes of HIV-1 integrase inhibitors.
  • To highlight the potential of integrase inhibitors as novel AIDS therapeutics.

Main Methods:

  • Literature review of HIV-1 integrase function and inhibition.
  • Analysis of various compound classes screened for integrase inhibitory properties.

Related Experiment Videos

  • Synthesis of current knowledge on the integration mechanism.

    • Main Results:

    • Significant advances in understanding the HIV-1 integration mechanism.
    • Identification of several classes of compounds with HIV-1 integrase inhibitory properties.
    • Despite progress, no clinically useful integrase inhibitors are currently available.

    Conclusions:

    • HIV-1 integrase remains a promising target for developing new AIDS therapies.
    • Integrase inhibitors offer potential for reduced toxicity and overcoming drug resistance.
    • Further research is needed to translate identified inhibitors into effective clinical treatments.